ACH

Accendra Health, Inc. (ACH) 10Y Growth Potential Analysis (2026)

Invetso Score: 4.9/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Revenue Growth Drivers

Score: 5.8 (Moderate)

ACH’s revenue base can still expand through fertilizer price and volume normalization, but peer growth is likely more cyclical than structurally compounding.

Low capex intensity supports incremental output growth without heavy reinvestment, yet peers with stronger downstream integration typically scale revenue more predictably.

Negative cash conversion cycle can temporarily fund working-capital-led growth, but it does not by itself create durable multi-year revenue compounding.

The absence of disclosed five-year revenue CAGR limits evidence of sustained historical scaling, leaving ACH less proven than higher-growth peers.

Market Tailwinds

Score:

ACH benefits from agricultural nutrient demand that can rise with crop intensity, but peers tied to specialty inputs often have clearer secular growth visibility.

Commodity fertilizer markets can support periodic demand surges, yet pricing cycles usually make long-term revenue growth less durable than diversified chemical peers.

Regional agricultural production trends can lift volumes over time, but ACH remains more exposed to cyclical farm economics than global compounders.

The company’s growth tailwinds are real but largely external, so peer-relative expansion potential depends more on market cycles than structural demand creation.

Scalability Expansion

Score:

ACH’s low capex-to-revenue ratio suggests some operating leverage, but peers with stronger pricing power and product differentiation usually scale faster.

ROIC of 6.4% indicates limited reinvestment efficiency, which constrains compounding versus peers that can redeploy capital at higher returns.

High leverage and weak interest coverage reduce financial flexibility, limiting the pace at which ACH can fund expansion relative to stronger balance-sheet peers.

The business can expand incrementally, but capital structure and commodity exposure make sustained scalable growth less reliable than for higher-quality peers.

Constraints Limitations

Score:

Net debt to EBITDA near 7.7x materially constrains reinvestment capacity, leaving ACH less able than peers to fund long-term expansion.

Interest coverage below 1.0x indicates limited earnings cushion, which can divert cash from growth investment toward balance-sheet support.

Commodity fertilizer exposure limits pricing durability, so peers with differentiated products generally have better long-term revenue stability and compounding potential.

The company’s growth profile is structurally capped by leverage and cyclicality, making sustained multi-year scaling harder than for less capital-stressed peers.

Overall Score

Score:

ACH has some revenue expansion capacity from agricultural demand and low capex needs, but heavy leverage and commodity cyclicality materially limit peer-relative long-term compounding.

Score Driver: Leverage Constrained Expansion

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Accendra Health, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →